# Adrian B Mcdermott

List of Publications by Year
in descending order



| | | | |
|---|---|---|---|
| 140 papers | 18,733 citations | 19657 61 h-index | 15732 125 g-index |
| 169 all docs | 169 docs citations | 169 times ranked | 21748 citing authors |

| # | Article | IF | Citations |
|---|---|---|---|
| 1 | Prediction of serum HIV-1 neutralization titers of VRC01 in HIV-uninfected Antibody Mediated Prevention (AMP) trial participants. Human Vaccines and Immunotherapeutics, 2022, 18, 1-10. | 3.3 | 6 |
| 2 | Stable Latent HIV Infection and Low-level Viremia Despite Treatment With the Broadly Neutralizing Antibody VRC07-523LS and the Latency Reversal Agent Vorinostat. Journal of Infectious Diseases, 2022, 225, 856-861. | 4.0 | 22 |
| 3 | Homologous and Heterologous Covid-19 Booster Vaccinations. New England Journal of Medicine, 2022, 386, 1046-1057. | 27.0 | 418 |
| 4 | Immune correlates analysis of the mRNA-1273 COVID-19 vaccine efficacy clinical trial. Science, 2022, 375, 43-50. | 12.6 | 788 |
| 5 | Safety and Pharmacokinetics of Monoclonal Antibodies VRC07-523LS and PGT121 Administered Subcutaneously for Human Immunodeficiency Virus Prevention. Journal of Infectious Diseases, 2022, 226, 510-520. | 4.0 | 13 |
| 6 | Enterovirus D68: a test case for the use of immunological surveillance to develop tools to mitigate the pandemic potential of emerging pathogens. Lancet Microbe, The, 2022, 3, e83-e85. | 7.3 | 10 |
| 7 | Safety and immunogenicity of a ferritin nanoparticle H2 influenza vaccine in healthy adults: a phase 1 trial. Nature Medicine, 2022, 28, 383-391. | 30.7 | 65 |
| 8 | A single residue in influenza virus H2 hemagglutinin enhances the breadth of the B cell response elicited by H2 vaccination. Nature Medicine, 2022, 28, 373-382. | 30.7 | 16 |
| 9 | Defining the risk of SARS-CoV-2 variants on immune protection. Nature, 2022, 605, 640-652. | 27.8 | 117 |
| 10 | mRNA-1273 or mRNA-Omicron boost in vaccinated macaques elicits similar B cell expansion, neutralizing responses, and protection from Omicron. Cell, 2022, 185, 1556-1571.e18. | 28.9 | 179 |
| 11 | Safety and tolerability of AAV8 delivery of a broadly neutralizing antibody in adults living with HIV: a phase 1, dose-escalation trial. Nature Medicine, 2022, 28, 1022-1030. | 30.7 | 34 |
| 12 | Structure of an influenza group 2-neutralizing antibody targeting the hemagglutinin stem supersite. Structure, 2022, , . | 3.3 | 1 |
| 13 | Tyrosine O-sulfation proteoforms affect HIV-1 monoclonal antibody potency. Scientific Reports, 2022, 12, 8433. | 3.3 | 8 |
| 14 | Safety and immunogenicity of an HIV-1 prefusion-stabilized envelope trimer (Trimer 4571) vaccine in healthy adults: A first-in-human open-label, randomized, dose-escalation, phase 1 clinical trial. EClinicalMedicine, 2022, 48, 101477. | 7.1 | 13 |
| 15 | Early human B cell signatures of the primary antibody response to mRNA vaccination. Proceedings of the National Academy of Sciences of the United States of America, 2022, 119, . | 7.1 | 17 |
| 16 | Durability of Responses after SARS-CoV-2 mRNA-1273 Vaccination. New England Journal of Medicine, 2021, 384, 80-82. | 27.0 | 665 |
| 17 | Model Informed Development of VRC01 in Newborn Infants Using a Population Pharmacokinetics Approach. Clinical Pharmacology and Therapeutics, 2021, 109, 184-192. | 4.7 | 6 |
| 18 | Recombinant MVA-prime elicits neutralizing antibody responses by inducing antigen-specific B cells in the germinal center. Npj Vaccines, 2021, 6, 15. | 6.0 | 5 |

| # | Article | IF | Citations |
|---|---|---|---|
| 19 | Pharmacokinetics and predicted neutralisation coverage of VRC01 in HIV-uninfected participants of the Antibody Mediated Prevention (AMP) trials. EBioMedicine, 2021, 64, 103203. | 6.1 | 14 |
| 20 | Development and deployment of COVID-19 vaccines for those most vulnerable. Science Translational Medicine, 2021, 13, . | 12.4 | 60 |
| 21 | A comprehensive influenza reporter virus panel for high-throughput deep profiling of neutralizing antibodies. Nature Communications, 2021, 12, 1722. | 12.8 | 41 |
| 22 | Coronavirus Occurrence in the Household Influenza Vaccine Evaluation (HIVE) Cohort of Michigan Households: Reinfection Frequency and Serologic Responses to Seasonal and Severe Acute Respiratory Syndrome Coronaviruses. Journal of Infectious Diseases, 2021, 224, 49-59. | 4.0 | 26 |
| 23 | Plasmodium falciparumâ€“specific IgM B cells dominate in children, expand with malaria, and produce functional IgM. Journal of Experimental Medicine, 2021, 218, . | 8.5 | 44 |
| 24 | Fusion peptide priming reduces immune responses to HIV-1 envelope trimer base. Cell Reports, 2021, 35, 108937. | 6.4 | 12 |
| 25 | A sensitive method to quantify HIV-1 antibodies in mucosal samples. Journal of Immunological Methods, 2021, 491, 112995. | 1.4 | 5 |
| 26 | B cell engagement with HIV-1 founder virus envelope predicts development of broadly neutralizing antibodies. Cell Host and Microbe, 2021, 29, 564-578.e9. | 11.0 | 18 |
| 27 | A majority of uninfected adults show preexisting antibody reactivity against SARS-CoV-2. JCI Insight, 2021, 6, . | 5.0 | 39 |
| 28 | Safety, Tolerability, and Pharmacokinetics of a Long-Acting Broadly Neutralizing Human Immunodeficiency Virus Type 1 (HIV-1) Monoclonal Antibody VRC01LS in HIV-1â€“Exposed Newborn Infants. Journal of Infectious Diseases, 2021, 224, 1916-1924. | 4.0 | 27 |
| 29 | Antibody Persistence through 6 Months after the Second Dose of mRNA-1273 Vaccine for Covid-19. New England Journal of Medicine, 2021, 384, 2259-2261. | 27.0 | 603 |
| 30 | A non-affinity purification process for GMP production of prefusion-closed HIV-1 envelope trimers from clades A and C for clinical evaluation. Vaccine, 2021, 39, 3379-3387. | 3.8 | 13 |
| 31 | Specific COVID-19 Symptoms Correlate with High Antibody Levels against SARS-CoV-2. ImmunoHorizons, 2021, 5, 466-476. | 1.8 | 23 |
| 32 | Ultrapotent antibodies against diverse and highly transmissible SARS-CoV-2 variants. Science, 2021, 373, . | 12.6 | 174 |
| 33 | Protective antibodies elicited by SARS-CoV-2 spike protein vaccination are boosted in the lung after challenge in nonhuman primates. Science Translational Medicine, 2021, 13, . | 12.4 | 56 |
| 34 | A Monoclonal Antibody for Malaria Prevention. New England Journal of Medicine, 2021, 385, 803-814. | 27.0 | 95 |
| 35 | mRNA-1273 protects against SARS-CoV-2 beta infection in nonhuman primates. Nature Immunology, 2021, 22, 1306-1315. | 14.5 | 57 |
| 36 | Rectal tissue and vaginal tissue from intravenous VRC01 recipients show protection against ex vivo HIV-1 challenge. Journal of Clinical Investigation, 2021, 131, . | 8.2 | 17 |

| # | Article | IF | Citations |
|---|---|---|---|
| 37 | Durability of mRNA-1273 vaccineâ€“induced antibodies against SARS-CoV-2 variants. Science, 2021, 373, 1372-1377. | 12.6 | 459 |
| 38 | Why are there so few (or so many) circulating coronaviruses?. Trends in Immunology, 2021, 42, 751-763. | 6.8 | 7 |
| 39 | Immune correlates of protection by mRNA-1273 vaccine against SARS-CoV-2 in nonhuman primates. Science, 2021, 373, eabj0299. | 12.6 | 244 |
| 40 | AZD1222/ChAdOx1 nCoV-19 vaccination induces a polyfunctional spike proteinâ€“specific T <sub>H</sub> 1 response with a diverse TCR repertoire. Science Translational Medicine, 2021, 13, eabj7211. | 12.4 | 80 |
| 41 | Sequential staining of HIV gp140 to capture antigen-specific human B cells via flow cytometry. STAR Protocols, 2021, 2, 100771. | 1.2 | 0 |
| 42 | Protection against SARS-CoV-2 Beta variant in mRNA-1273 vaccineâ€“boosted nonhuman primates. Science, 2021, 374, 1343-1353. | 12.6 | 83 |
| 43 | Variant SARS-CoV-2 mRNA vaccines confer broad neutralization as primary or booster series in mice. Vaccine, 2021, 39, 7394-7400. | 3.8 | 63 |
| 44 | A multiclade envâ€“gag VLP mRNA vaccine elicits tier-2 HIV-1-neutralizing antibodies and reduces the risk of heterologous SHIV infection in macaques. Nature Medicine, 2021, 27, 2234-2245. | 30.7 | 80 |
| 45 | Immune correlates analysis of the mRNA-1273 COVID-19 vaccine efficacy clinical trial. Science, 2021, , eab3435. | 12.6 | 145 |
| 46 | Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older Adults. New England Journal of Medicine, 2020, 383, 2427-2438. | 27.0 | 1,242 |
| 47 | A Hyper-IgM Syndrome Mutation in Activation-Induced Cytidine Deaminase Disrupts G-Quadruplex Binding and Genome-wide Chromatin Localization. Immunity, 2020, 53, 952-970.e11. | 14.3 | 21 |
| 48 | An mRNA Vaccine against SARS-CoV-2 â€” Preliminary Report. New England Journal of Medicine, 2020, 383, 1920-1931. | 27.0 | 2,719 |
| 49 | Development and Assessment of a Pooled Serum as Candidate Standard to Measure Influenza A Virus Group 1 Hemagglutinin Stalk-Reactive Antibodies. Vaccines, 2020, 8, 666. | 4.4 | 6 |
| 50 | Evaluation of the mRNA-1273 Vaccine against SARS-CoV-2 in Nonhuman Primates. New England Journal of Medicine, 2020, 383, 1544-1555. | 27.0 | 936 |
| 51 | Immune Monitoring Reveals Fusion Peptide Priming to Imprint Cross-Clade HIV-Neutralizing Responses with a Characteristic Early B Cell Signature. Cell Reports, 2020, 32, 107981. | 6.4 | 15 |
| 52 | The Transcription Factor T-bet Resolves Memory B Cell Subsets with Distinct Tissue Distributions and Antibody Specificities in Mice and Humans. Immunity, 2020, 52, 842-855.e6. | 14.3 | 144 |
| 53 | Convergent Evolution in Breadth of Two VH6-1-Encoded Influenza Antibody Clonotypes from a Single Donor. Cell Host and Microbe, 2020, 28, 434-444.e4. | 11.0 | 16 |
| 54 | Glycan repositioning of influenza hemagglutinin stem facilitates the elicitation of protective cross-group antibody responses. Nature Communications, 2020, 11, 791. | 12.8 | 36 |

| # | Article | IF | Citations |
|---|---|---|---|
| 55 | Higher PIK3C2B gene expression of H1N1+ specific B-cells is associated with lower H1N1 immunogenicity after trivalent influenza vaccination in HIV infected children. Clinical Immunology, 2020, 215, 108440. | 3.2 | 10 |
| 56 | Development of a 3Mut-Apex-Stabilized Envelope Trimer That Expands HIV-1 Neutralization Breadth When Used To Boost Fusion Peptide-Directed Vaccine-Elicited Responses. Journal of Virology, 2020, 94, . | 3.4 | 21 |
| 57 | Potent Zika and dengue cross-neutralizing antibodies induced by Zika vaccination in a dengue-experienced donor. Nature Medicine, 2020, 26, 228-235. | 30.7 | 61 |
| 58 | A Global Immunological Observatory to meet a time of pandemics. ELife, 2020, 9, . | 6.0 | 52 |
| 59 | Activation Dynamics and Immunoglobulin Evolution of Pre-existing and Newly Generated Human Memory B cell Responses to Influenza Hemagglutinin. Immunity, 2019, 51, 398-410.e5. | 14.3 | 107 |
| 60 | Safety and pharmacokinetics of broadly neutralising human monoclonal antibody VRC07-523LS in healthy adults: a phase 1 dose-escalation clinical trial. Lancet HIV,the, 2019, 6, e667-e679. | 4.7 | 67 |
| 61 | Safety, tolerability, pharmacokinetics, and immunogenicity of the therapeutic monoclonal antibody mAb114 targeting Ebola virus glycoprotein (VRC 608): an open-label phase 1 study. Lancet, The, 2019, 393, 889-898. | 13.7 | 99 |
| 62 | Dynamic Perspectives on the Search for a Universal Influenza Vaccine. Journal of Infectious Diseases, 2019, 219, S46-S56. | 4.0 | 18 |
| 63 | Outflanking immunodominance to target subdominant broadly neutralizing epitopes. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 13474-13479. | 7.1 | 57 |
| 64 | Safety and efficacy of VRC01 broadly neutralising antibodies in adults with acutely treated HIV (RV397): a phase 2, randomised, double-blind, placebo-controlled trial. Lancet HIV,the, 2019, 6, e297-e306. | 4.7 | 73 |
| 65 | Prolonged evolution of the memory B cell response induced by a replicating adenovirus-influenza H5 vaccine. Science Immunology, 2019, 4, . | 11.9 | 40 |
| 66 | Design of Nanoparticulate Group 2 Influenza Virus Hemagglutinin Stem Antigens That Activate Unmutated Ancestor B Cell Receptors of Broadly Neutralizing Antibody Lineages. MBio, 2019, 10, . | 4.1 | 88 |
| 67 | Longitudinal Analysis Reveals Early Development of Three MPER-Directed Neutralizing Antibody Lineages from an HIV-1-Infected Individual. Immunity, 2019, 50, 677-691.e13. | 14.3 | 77 |
| 68 | Immunization with Components of the Viral Fusion Apparatus Elicits Antibodies That Neutralize Epstein-Barr Virus in B Cells and Epithelial Cells. Immunity, 2019, 50, 1305-1316.e6. | 14.3 | 107 |
| 69 | Associating HIV-1 envelope glycoprotein structures with states on theÂvirus observed by smFRET. Nature, 2019, 568, 415-419. | 27.8 | 156 |
| 70 | Single Cell Profiling Reveals PTEN Overexpression in Influenza-Specific B cells in Aging HIV-infected individuals on Anti-retroviral Therapy. Scientific Reports, 2019, 9, 2482. | 3.3 | 19 |
| 71 | Mosaic nanoparticle display of diverse influenza virus hemagglutinins elicits broad B cell responses. Nature Immunology, 2019, 20, 362-372. | 14.5 | 211 |
| 72 | Overexpression of T-bet in HIV infection is associated with accumulation of B cells outside germinal centers and poor affinity maturation. Science Translational Medicine, 2019, 11, . | 12.4 | 65 |

| # | Article | IF | Citations |
|---|---|---|---|
| 73 | Immunity to Influenza: Catching a Moving Target To Improve Vaccine Design. Journal of Immunology, 2019, 202, 327-331. | 0.8 | 4 |
| 74 | Hemagglutinin head-specific responses dominate over stem-specific responses following prime boost with mismatched vaccines. JCI Insight, 2019, 4, . | 5.0 | 15 |
| 75 | Intranasal Live Influenza Vaccine Priming Elicits Localized B Cell Responses in Mediastinal Lymph Nodes. Journal of Virology, 2018, 92, . | 3.4 | 30 |
| 76 | A human monoclonal antibody prevents malaria infection by targeting a new site of vulnerability on the parasite. Nature Medicine, 2018, 24, 408-416. | 30.7 | 235 |
| 77 | Is It Possible to Develop a â€œUniversalâ€•Influenza Virus Vaccine?. Cold Spring Harbor Perspectives in Biology, 2018, 10, a029413. | 5.5 | 34 |
| 78 | Quantitative Multiplexed Imaging Analysis Reveals a Strong Association between Immunogen-Specific B Cell Responses and Tonsillar Germinal Center Immune Dynamics in Children after Influenza Vaccination. Journal of Immunology, 2018, 200, 538-550. | 0.8 | 38 |
| 79 | Vectored delivery of anti-SIV envelope targeting mAb via AAV8 protects rhesus macaques from repeated limiting dose intrarectal swarm SIVsmE660 challenge. PLoS Pathogens, 2018, 14, e1007395. | 4.7 | 37 |
| 80 | Shaping a universally broad antibody response to influenza amidst a variable immunoglobulin landscape. Current Opinion in Immunology, 2018, 53, 96-101. | 5.5 | 25 |
| 81 | Epitope-based vaccine design yields fusion peptide-directed antibodies that neutralize diverse strains of HIV-1. Nature Medicine, 2018, 24, 857-867. | 30.7 | 256 |
| 82 | Safety and pharmacokinetics of the Fc-modified HIV-1 human monoclonal antibody VRC01LS: A Phase 1 open-label clinical trial in healthy adults. PLoS Medicine, 2018, 15, e1002493. | 8.4 | 174 |
| 83 | Accumulation of follicular CD8+ T cells in pathogenic SIV infection. Journal of Clinical Investigation, 2018, 128, 2089-2103. | 8.2 | 43 |
| 84 | Follicular CD8 T cells accumulate in HIV infection and can kill infected cells in vitro via bispecific antibodies. Science Translational Medicine, 2017, 9, . | 12.4 | 135 |
| 85 | Structure-Based Design of a Soluble Prefusion-Closed HIV-1 Env Trimer with Reduced CD4 Affinity and Improved Immunogenicity. Journal of Virology, 2017, 91, . | 3.4 | 81 |
| 86 | Defining B cell immunodominance to viruses. Nature Immunology, 2017, 18, 456-463. | 14.5 | 218 |
| 87 | Quantification of the Impact of the HIV-1-Glycan Shield on Antibody Elicitation. Cell Reports, 2017, 19, 719-732. | 6.4 | 160 |
| 88 | The aryl hydrocarbon receptor controls cell-fate decisions in B cells. Journal of Experimental Medicine, 2017, 214, 197-208. | 8.5 | 83 |
| 89 | Preferential induction of cross-group influenza A hemagglutinin stemâ€“specific memory B cells after H7N9 immunization in humans. Science Immunology, 2017, 2, . | 11.9 | 84 |
| 90 | Crystal structures of trimeric HIV envelope with entry inhibitors BMS-378806 and BMS-626529. Nature Chemical Biology, 2017, 13, 1115-1122. | 8.0 | 110 |

| # | Article | IF | Citations |
|---|---|---|---|
| 91 | Soluble Prefusion Closed DS-SOSIP.664-Env Trimers of Diverse HIV-1 Strains. Cell Reports, 2017, 21, 2992-3002. | 6.4 | 69 |
| 92 | An avian influenza H7 DNA priming vaccine is safe and immunogenic in a randomized phase I clinical trial. Npj Vaccines, 2017, 2, 15. | 6.0 | 24 |
| 93 | Longitudinal dynamics of the HIV-specific B cell response during intermittent treatment of primary HIV infection. PLoS ONE, 2017, 12, e0173577. | 2.5 | 5 |
| 94 | Safety and Immunogenicity of a rAd35-EnvA Prototype HIV-1 Vaccine in Combination with rAd5-EnvA in Healthy Adults (VRC 012). PLoS ONE, 2016, 11, e0166393. | 2.5 | 14 |
| 95 | Vaccine-Induced Antibodies that Neutralize Group 1 and Group 2 Influenza A Viruses. Cell, 2016, 166, 609-623. | 28.9 | 270 |
| 96 | Reconstituted B cell receptor signaling reveals carbohydrate-dependent mode of activation. Scientific Reports, 2016, 6, 36298. | 3.3 | 29 |
| 97 | Maintenance of HIV-Specific Memory B-Cell Responses in Elite Controllers Despite Low Viral Burdens. Journal of Infectious Diseases, 2016, 214, 390-398. | 4.0 | 43 |
| 98 | Adjuvant-dependent innate and adaptive immune signatures of risk of SIVmac251 acquisition. Nature Medicine, 2016, 22, 762-770. | 30.7 | 197 |
| 99 | Immunogenicity of a Prefusion HIV-1 Envelope Trimer in Complex with a Quaternary-Structure-Specific Antibody. Journal of Virology, 2016, 90, 2740-2755. | 3.4 | 58 |
| 100 | Structures of HIV-1 Env V1V2 with broadly neutralizing antibodies reveal commonalities that enable vaccine design. Nature Structural and Molecular Biology, 2016, 23, 81-90. | 8.2 | 162 |
| 101 | Hemagglutinin of Influenza A Virus Antagonizes Type I Interferon (IFN) Responses by Inducing Degradation of Type I IFN Receptor 1. Journal of Virology, 2016, 90, 2403-2417. | 3.4 | 68 |
| 102 | Safety, pharmacokinetics and neutralization of the broadly neutralizing HIV-1 human monoclonal antibody VRC01 in healthy adults. Clinical and Experimental Immunology, 2015, 182, 289-301. | 2.6 | 222 |
| 103 | Single-Chain Soluble BG505.SOSIP gp140 Trimers as Structural and Antigenic Mimics of Mature Closed HIV-1 Env. Journal of Virology, 2015, 89, 5318-5329. | 3.4 | 125 |
| 104 | Reversible Reprogramming of Circulating Memory T Follicular Helper Cell Function during Chronic HIV Infection. Journal of Immunology, 2015, 195, 5625-5636. | 0.8 | 74 |
| 105 | A Simple Flow-Cytometric Method Measuring B Cell Surface Immunoglobulin Avidity Enables Characterization of Affinity Maturation to Influenza A Virus. MBio, 2015, 6, e01156. | 4.1 | 34 |
| 106 | Virologic effects of broadly neutralizing antibody VRC01 administration during chronic HIV-1 infection. Science Translational Medicine, 2015, 7, 319ra206. | 12.4 | 390 |
| 107 | Quality and quantity of T <sub>FH</sub> cells are critical for broad antibody development in SHIV <sub>AD8</sub> infection. Science Translational Medicine, 2015, 7, 298ra120. | 12.4 | 119 |
| 108 | H5N1 Vaccineâ€“Elicited Memory B Cells Are Genetically Constrained by the IGHV Locus in the Recognition of a Neutralizing Epitope in the Hemagglutinin Stem. Journal of Immunology, 2015, 195, 602-610. | 0.8 | 83 |

| # | Article | IF | Citations |
|---|---|---|---|
| 109 | Crystal structure, conformational fixation and entry-related interactions of mature ligand-free HIV-1 Env. Nature Structural and Molecular Biology, 2015, 22, 522-531. | 8.2 | 333 |
| 110 | Rational Design of an Epstein-Barr Virus Vaccine Targeting the Receptor-Binding Site. Cell, 2015, 162, 1090-1100. | 28.9 | 278 |
| 111 | Head-to-Head Comparison of Poxvirus NYVAC and ALVAC Vectors Expressing Identical HIV-1 Clade C Immunogens in Prime-Boost Combination with Env Protein in Nonhuman Primates. Journal of Virology, 2015, 89, 8525-8539. | 3.4 | 35 |
| 112 | Homologous Boosting with Adenoviral Serotype 5 HIV Vaccine (rAd5) Vector Can Boost Antibody Responses despite Preexisting Vector-Specific Immunity in a Randomized Phase I Clinical Trial. PLoS ONE, 2014, 9, e106240. | 2.5 | 5 |
| 113 | Abnormal B cell memory subsets dominate HIV-specific responses in infected individuals. Journal of Clinical Investigation, 2014, 124, 3252-3262. | 8.2 | 130 |
| 114 | Loss of Circulating CD4 T Cells with B Cell Helper Function during Chronic HIV Infection. PLoS Pathogens, 2014, 10, e1003853. | 4.7 | 153 |
| 115 | Flow Cytometry Reveals that H5N1 Vaccination Elicits Cross-Reactive Stem-Directed Antibodies from Multiple Ig Heavy-Chain Lineages. Journal of Virology, 2014, 88, 4047-4057. | 3.4 | 220 |
| 116 | HIV vaccine research and discovery in the nonhuman primates model. Current Opinion in HIV and AIDS, 2013, 8, 1. | 3.8 | 13 |
| 117 | A Multiplex Microsphere-Based Immunoassay Increases the Sensitivity of SIV-Specific Antibody Detection in Serum Samples and Mucosal Specimens Collected from Rhesus Macaques Infected with SIVmac239. BioResearch Open Access, 2013, 2, 171-178. | 2.6 | 13 |
| 118 | Virus Inhibition Activity of Effector Memory CD8 <sup>+</sup> T Cells Determines Simian Immunodeficiency Virus Load in Vaccinated Monkeys after Vaccine Breakthrough Infection. Journal of Virology, 2012, 86, 5877-5884. | 3.4 | 37 |
| 119 | Lymph node T cell responses predict the efficacy of live attenuated SIV vaccines. Nature Medicine, 2012, 18, 1673-1681. | 30.7 | 130 |
| 120 | CD8+ T cells in preventing HIV infection and disease. Aids, 2012, 26, 1281-1292. | 2.2 | 71 |
| 121 | AIDS Vaccines and Preexposure Prophylaxis: Is Synergy Possible?. AIDS Research and Human Retroviruses, 2011, 27, 669-680. | 1.1 | 28 |
| 122 | DNA/Ad5 vaccination with SIV epitopes induced epitope-specific CD4+ T cells, but few subdominant epitope-specific CD8+ T cells. Vaccine, 2011, 29, 7483-7490. | 3.8 | 6 |
| 123 | Enhanced Control of Pathogenic Simian Immunodeficiency Virus SIVmac239 Replication in Macaques Immunized with an Interleukin-12 Plasmid and a DNA Prime-Viral Vector Boost Vaccine Regimen. Journal of Virology, 2011, 85, 9578-9587. | 3.4 | 63 |
| 124 | The TRIM5Î± Genotype of Rhesus Macaques Affects Acquisition of Simian Immunodeficiency Virus SIVsmE660 Infection after Repeated Limiting-Dose Intrarectal Challenge. Journal of Virology, 2011, 85, 9637-9640. | 3.4 | 60 |
| 125 | Macaques Vaccinated with Simian Immunodeficiency Virus SIVmac239Î”nef Delay Acquisition and Control Replication after Repeated Low-Dose Heterologous SIV Challenge. Journal of Virology, 2010, 84, 9190-9199. | 3.4 | 58 |
| 126 | Macaques vaccinated with live-attenuated SIV control replication of heterologous virus. Journal of Experimental Medicine, 2008, 205, 2537-2550. | 8.5 | 139 |

| # | Article | IF | Citations |
|---|---|---|---|
| 127 | HIV vaccine design: insights from live attenuated SIV vaccines. Nature Immunology, 2006, 7, 19-23. | 14.5 | 235 |
| 128 | Vaccine-Induced Cellular Immune Responses Reduce Plasma Viral Concentrations after Repeated Low-Dose Challenge with Pathogenic Simian Immunodeficiency Virus SIVmac239. Journal of Virology, 2006, 80, 5875-5885. | 3.4 | 237 |
| 129 | Cytotoxic T-Lymphocyte Escape Does Not Always Explain the Transient Control of Simian Immunodeficiency Virus SIVmac239 Viremia in Adenovirus-Boosted and DNA-Primed Mamu-A*01-Positive Rhesus Macaques. Journal of Virology, 2005, 79, 15556-15566. | 3.4 | 53 |
| 130 | Attenuation of Simian Immunodeficiency Virus SIVmac239 Infection by Prophylactic Immunization with DNA and Recombinant Adenoviral Vaccine Vectors Expressing Gag. Journal of Virology, 2005, 79, 15547-15555. | 3.4 | 249 |
| 131 | Repeated Low-Dose Mucosal Simian Immunodeficiency Virus SIVmac239 Challenge Results in the Same Viral and Immunological Kinetics as High-Dose Challenge: a Model for the Evaluation of Vaccine Efficacy in Nonhuman Primates. Journal of Virology, 2004, 78, 3140-3144. | 3.4 | 95 |
| 132 | A Dominant Role for CD8 + -T-Lymphocyte Selection in Simian Immunodeficiency Virus Sequence Variation. Journal of Virology, 2004, 78, 14012-14022. | 3.4 | 89 |
| 133 | Consequences of Cytotoxic T-Lymphocyte Escape: Common Escape Mutations in Simian Immunodeficiency Virus Are Poorly Recognized in Naĩve Hosts. Journal of Virology, 2004, 78, 10064-10073. | 3.4 | 35 |
| 134 | Major Histocompatibility Complex Class I Alleles Associated with Slow Simian Immunodeficiency Virus Disease Progression Bind Epitopes Recognized by Dominant Acute-Phase Cytotoxic-T-Lymphocyte Responses. Journal of Virology, 2003, 77, 9029-9040. | 3.4 | 170 |
| 135 | A novel technique for the fluorometric assessment of T lymphocyte antigen specific lysis. Journal of Immunological Methods, 2001, 249, 99-110. | 1.4 | 150 |
| 136 | A simple and rapid magnetic bead separation technique for the isolation of tetramer-positive virus-specific CD8 T cells. Aids, 2001, 15, 810-812. | 2.2 | 12 |
| 137 | Complementary strand analysis: a new approach for allelic separation in complex polyallelic genetic systems. Nucleic Acids Research, 1997, 25, 2236-2238. | 14.5 | 19 |
| 138 | Contribution of human leukocyte antigens to the antibody response to hepatitis B vaccination. Tissue Antigens, 1997, 50, 8-14. | 1.0 | 102 |
| 139 | T-Bet Enables Tissue-Restricted B Cell Memory and Influenza Hemagglutinin Stalk-Specific Antibodies. SSRN Electronic Journal, 0, , . | 0.4 | 2 |
| 140 | Antibody Reactivity Against SARS-CoV-2 in Adults from the Vancouver Metropolitan Area, Canada. SSRN Electronic Journal, 0, , . | 0.4 | 0 |